Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting

2021-05-11 04:15:50

(MENAFN- PR Newswire) SAN DIEGO, May 11, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week (DDW) meeting, being held May 21-23. Along with clinical collaborators, Prometheus will present two oral presentations, one during a plenary session; and five posters, two named as Posters of Distinction.

"The data presented at DDW this year represents our commitment to advancing precision-guided clinical testing to optimize individual treatment outcomes," commented Dr. Thierry Dervieux, Chief Scientific Officer. "It also underscores the value of our unparalleled biorepository and database in contributing to the development and validation of novel diagnostic solutions to improve patient outcomes."

The data presented at DDW will include:

A model-informed precision dosing tool for adalimumab which was developed and evaluated utilizing Prometheus Anser® testing on a clinical cohort of 7,755 IBD patients. Results point to the potential use of such a model to help improve dose optimization; and
Results from a study evaluating the combination of serum infliximab levels and an endoscopic healing index score with two Prometheus services, Anser and Monitr™, in patients with Crohn's Disease (CD) to guide dose optimization. The data indicates the potential to allow clinicians to distinguish pharmacokinetic from pharmacodynamic failure, and thus guide therapeutic decision-making in patients with CD.

Presentations and posters highlighting data from Prometheus Lab at DDW 2021 are below:

Abstract	Title	Date/Time/Session
Oral Presentation
Plenary session 780	HOST SEROREACTIVITY TO MICROBIAL ANTIGENS IS ASSOCIATED WITH FUTURE ONSET OF CROHN''S DISEASE INDEPENDENT OF GUT BARRIER FUNCTION, SUBCLINICAL INFLAMMATION, AND GENETIC RISK	Sunday, May 23, 2021 from 3:30 PM to 5:00 PM EDTImmunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Distinguished Abstract Plenary
Lecture Presentation854	RISK OF IMMUNOGENICITY TO A SUBSEQUENT THERAPY IS THE HIGHEST DURING THE FIRST YEAR AFTER A SWITCH IN THERAPY IN IMMUNOGENIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE	Sunday, May 23, 2021 from 5:30 PM to 7:00 PM EDTBiologic and Disease Monitoring in IBD
Posters
Poster of DistinctionSu432	IMPACT OF THIOPURINE EXPOSURE ON IMMUNOGENICITY TO INFLIXIMAB IS NEGLIGIBLE IN THE SETTING OF ELEVATED INFLIXIMAB CONCENTRATIONS	Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDTTherapeutic Monitoring
Poster of DistinctionSu457	DOES PREOPERATIVE SERUM USTEKINUMAB CONCENTRATION PREDICT THIRTY-DAY POSTOPERATIVE OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING ABDOMINAL SURGERY?	Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDTImmunology‚ Microbiology & Inflammatory Bowel Diseases: IBD: Uncontrolled Therapeutic Observations in Humans Biologic
Su444	MODEL INFORMED PRECISION DOSING OF ADALIMUMAB BY INDIVIDUALIZED PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES	Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDTTherapeutic Monitoring
Su469	TUMOR NECROSIS FACTOR IMPACTS INFLIXIMAB CLEARANCE IN INFLAMMATORY BOWEL DISEASES	Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDTUncontrolled Therapeutic Observations in Humans Biologic
Su439	THE VALUE OF COMBINED SERUM INFLIXIMAB AND ENDOSCOPIC HEALING INDEX MONITORING FOR GUIDING INFLIXIMAB DOSING IN PATIENTS WITH CROHN''S DISEASE	Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDTTherapeutic Monitoring

The complete abstracts can be found on the .

About Prometheus Laboratories Prometheus Laboratories is a specialty clinical laboratory, which enables precision-guided care in Inflammatory Bowel Disease and other GI disorders. We discover, develop and commercialize testing services that help clinicians improve outcomes across the patient journey, from disease interception and stratification, to therapy selection, optimization and monitoring. For more information, please visit , visit our virtual booth at DDW 2021, or engage with us on .

About Anser Anser testing uniquely measures serum drug (infliximab or infliximab biosimilars, adalimumab, ustekinumab, vedolizumab) and antidrug antibody levels using a proprietary, drug tolerant, homogenous mobility shift assay technology. Anser testing aids in the assessment and optimization of biologic therapy management decisions.

About Monitr Monitr is a first-of-its-kind, non-invasive, multi-protein serum biomarker test developed and validated to assess endoscopic disease activity in patients with CD. The test aids in distinguishing CD patients in endoscopic remission from those with active disease, providing an endoscopic healing index for objective evaluation of mucosal healing.

Investor and Media Contact Amy ConradJuniper Point(858) 914-1962

SOURCE Prometheus Laboratories, Inc.